142 related articles for article (PubMed ID: 25641453)
1. Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: our experience and review of the literature.
Sarıkaya S; Resorlu M; Oguz U; Yordam M; Bozkurt OF; Unsal A
Arch Ital Urol Androl; 2014 Dec; 86(4):288-90. PubMed ID: 25641453
[TBL] [Abstract][Full Text] [Related]
2. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY
Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
[TBL] [Abstract][Full Text] [Related]
3. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies.
Dimmen M; Vlatkovic L; Hole KH; Nesland JM; Brennhovd B; Axcrona K
BJU Int; 2012 Jul; 110(2 Pt 2):E69-75. PubMed ID: 22093091
[TBL] [Abstract][Full Text] [Related]
4. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z
Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321
[TBL] [Abstract][Full Text] [Related]
5. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
Janbaziroudsari H; Mirzaei A; Maleki N
Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
[TBL] [Abstract][Full Text] [Related]
6. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
7. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
Park HK; Hong SK; Byun SS; Lee SE
Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
[TBL] [Abstract][Full Text] [Related]
8. Saturation biopsy technique increase the capacity to diagnose adenocarcinoma of prostate in patients with PSA < 10 ng/ml, after a first negative biopsy.
Giulianelli R; Brunori S; Gentile BC; Vincenti G; Nardoni S; Pisanti F; Shestani T; Mavilla L; Albanesi L; Attisani F; Mirabile G; Schettini M
Arch Ital Urol Androl; 2011 Sep; 83(3):154-9. PubMed ID: 22184840
[TBL] [Abstract][Full Text] [Related]
9. How many cores should be taken in a repeat biopsy on patients in whom atypical small acinar proliferation has been identified in an initial transrectal prostate biopsy?
Aglamis E; Kocaarslan R; Yucetas U; Toktas G; Ceylan C; Doluoglu OG; Unluer E
Int Braz J Urol; 2014; 40(5):605-12. PubMed ID: 25498271
[TBL] [Abstract][Full Text] [Related]
10. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
Inahara M; Suzuki H; Kojima S; Komiya A; Fukasawa S; Imamoto T; Naya Y; Ichikawa T
Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
12. Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.
Leone A; Gershman B; Rotker K; Butler C; Fantasia J; Miller A; Afiadata A; Amin A; Zhou A; Jiang Z; Sebo T; Mega A; Schiff S; Pareek G; Golijanin D; Yates J; Karnes RJ; Renzulli J
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):68-71. PubMed ID: 26857145
[TBL] [Abstract][Full Text] [Related]
13. [Is it convenient in a screening programme for prostate tumour to do biopsy in people with PSA between 3 and 3.9 ng/ml?].
Parravicini M; Del Boca C
Arch Ital Urol Androl; 2003 Jun; 75(2):99-101. PubMed ID: 12868147
[TBL] [Abstract][Full Text] [Related]
14. Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment?
Brausi M; Castagnetti G; Dotti A; De Luca G; Olmi R; Cesinaro AM
J Urol; 2004 Sep; 172(3):906-8; discussion 908-9. PubMed ID: 15310995
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≤ 15 ng/ml and normal digital rectal examination: a 10-year prospective follow-up study of 427 consecutive patients.
Mohamed ZK; Dominguez-Escrig J; Vasdev N; Bharathan B; Greene D
Urol Oncol; 2013 Nov; 31(8):1489-96. PubMed ID: 22591749
[TBL] [Abstract][Full Text] [Related]
16. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
17. Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies.
Scattoni V; Roscigno M; Freschi M; Dehò F; Raber M; Briganti A; Fantini G; Nava L; Montorsi F; Rigatti P
Arch Ital Urol Androl; 2005 Mar; 77(1):31-6. PubMed ID: 15906787
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Men S; Cakar B; Conkbayir I; Hekimoglu B
J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
[TBL] [Abstract][Full Text] [Related]
19. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Presti JC; Hovey R; Carroll PR; Shinohara K
J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
